SGLT2 Inhibitors & GLP-1 Receptor Agonists: Differences, Similarities, Patient Selection

Newer classes of diabetes drugs have brought a paradigm shift in diabetes management. Several large cardiovascular outcome trials suggest that SGLT2 inhibitors and GLP1 receptor agonists both decrease cardiovascular risk, and some studies suggest a role for renoprotection.

Recent research raises several important questions: Is there a difference between SGLT2 inhibitors and GLP1 agonists for cardiovascular and renal protection? If so, which one is better, and for which patients? Evidence and guidance follow.